Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.850
-0.040 (-2.12%)
At close: Apr 28, 2026, 4:00 PM EDT
1.854
+0.004 (0.22%)
After-hours: Apr 28, 2026, 4:56 PM EDT
Annovis Bio Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Annovis Bio stock have an average target of 13.5, with a low estimate of 10 and a high estimate of 17. The average target predicts an increase of 629.73% from the current stock price of 1.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Annovis Bio stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +818.92% | Apr 14, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +818.92% | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +440.54% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $12 | Strong Buy | Maintains | $30 → $12 | +548.65% | Jun 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $26 → $17 | Strong Buy | Maintains | $26 → $17 | +818.92% | May 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.40
from -1.40
EPS Next Year
-1.20
from -1.40
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.16 | -1.13 | ||||||
| Avg | -1.40 | -1.20 | ||||||
| Low | -1.48 | -1.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.